Skip to main content
SpringerLink
Log in

Langzeitmanagement des atopischen Ekzems bei Kindern mit Calcineurininhibitoren

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Calcineurininhibitoren Pimecrolimus und Tacrolimus spielen eine zunehmende Rolle im Therapiespektrum des atopischen Ekzems bei Kindern. Sie sind derzeit in Deutschland für die intermittierende Langzeitbehandlung der mittelschweren bis schweren (Tacrolimussalbe 0,03%) bzw. leichten bis mittelschweren (Pimecrolimuscreme 1%) Formen des atopischen Ekzems bei Kindern (ab 2 Jahre) zugelassen. Neueste Studienergebnisse deuten an, dass auch Säuglinge und Kleinkinder (3–23 Monate) von der Therapie mit Pimecrolimuscreme profitieren können. Unter Langzeitanwendung wurden bei Kindern aller Altersgruppen die erzielten Therapieerfolge beibehalten sowie eine kontinuierliche Steigerung der Ansprechrate beobachtet. Das Langzeitmanagement des atopischen Ekzems wird durch gute lokale und systemische Verträglichkeit, Reduktion der Ekzemschübe und Verringerung der Steroidmenge positiv beeinflusst.

Abstract

The calcineurin inhibitors pimecrolimus and tacrolimus are important tools for long-term management of atopic dermatitis in childhood. These drugs are approved in Germany for the intermittent long-term treatment of moderate to severe (tacrolimus ointment) or mild to moderate (pimecrolimus cream) atopic dermatitis in children older than 2 years. Recent study results show that these agents are also effective in infants (aged 3–23 months) with atopic dermatitis. During the long-term treatment of children and infants with calcineurin inhibitors, the therapeutic success can be maintained and there is a continuous increase in the response rate. Long-term use of calcineurin inhibitors in atopic dermatitis is well tolerated locally and systemically, leads to reduction of disease flares and has a corticosteroid sparing effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1.
Abb. 2.
Abb. 3.

Literatur

  1. Schultz LF, Diepgen T, Svensson A (1996) The occurrence of atopic dermatitis in North Europe: an international questionnaire study. J Am Acad Dermatol 34:760–764

    Google Scholar 

  2. Williams H, Robertson C, Stewart A et al. (1999) Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Children. J Allergy Clin Immunol 103:125–138

    Google Scholar 

  3. Raimer SS (2000) Managing pediatric atopic dermatitis. Clin Pediatr 39:1–14

    Google Scholar 

  4. Drake L, Dinehart SM, Farmer ER et al. (1996) Guidelines of care for the use of topical glucocorticosteroids J Am Acad Dermatol 35:615–619

    Google Scholar 

  5. Charman C, Morris AD, Williams HC (2000) Topical corticosteroid phobia in patients with atopic dermatitis. Br J Dermatol 142:931–936

    Google Scholar 

  6. Stuetz A, Grassberger M, Meingassner JG (2001) Pimecrolimus (Elidel, SDZ ASM 981)—preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 20:233–241

    Google Scholar 

  7. Cheer SM, Plosker GL (2001) Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2:389–406

    Google Scholar 

  8. Queille-Roussel C Paul C, Duteil L et al. (2001) The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: a randomised, double-blind controlled study. Br J Dermatol 144:507–513

    Google Scholar 

  9. Reitamo S, Rissanen J, Remitz A et al. (1998) Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 111:396–398

    Google Scholar 

  10. Harper J (2002) Tacrolimus ointment 0,03% shows minimal systemic absorbtion in paediatric patients with atopic dermatitis. JEADV 16 [Suppl 1]:136 (Abstract)

  11. Harper J, Lakhanpaul M, Wahn U et al.(2001) Pimecrolimus (Elidel®, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic eczema. JEADV 15 [Suppl 2]:109

  12. Paller A, Eichenfield LF, Leung DY et al. (2001) A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 44:S47–S57

    Google Scholar 

  13. Ruzicka T, Bieber T, Schopf E et al. (1997) A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 337:816–821

    Google Scholar 

  14. Reitamo S, Van Leent EJM, Ho V et al. (2002) Efficacy and safety of tacrolimus ointment compared with hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol109:539–546

    Google Scholar 

  15. Harper J, Green A, Scott G et al. (2001) First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 144:781–787

    Google Scholar 

  16. Eichenfield LF, Lucky AW, Boguniewicz M et al. (2002) Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of atopic dermatitis in children and adolescents. J Am Acad Dermatol 46:495–504

    Google Scholar 

  17. Drake L, Prendergast M, Maher R et al.(2001) The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 44 [1 Suppl]:S65–72

  18. Whalley D, Huels J, McKenna SP, van Assche D (in press) The benefit of pimecrolimus (Elidel, SDZ ASM 981) on quality of life in the treatment of paediatric atopic dermatitis. Pediatrics 2003

  19. Kang S, Lucky AW, Pariser D et al. (2001) Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 44:S58–S64

    Google Scholar 

  20. Paller AS (2002) Long-term safety of topically applied tacrolimus ointment in pediatric patients 2–15 years of age with atopic dermatitis. 60th Annual Meeting of the AAD, New Orleans, LA: Poster 104

  21. Remitz A, Kyllonen H, Granlund H, Reitamo S (2001) Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 107:196–197

    Google Scholar 

  22. Lübbe J, Pournaras CC, Saurat JH (2000) Eczema herpeticum during treatment of atopic dermatitis with 0,1% tacrolimus ointment. Dermatology 201:249–251

    Google Scholar 

  23. Hanifin J, Ho V, Kaufmann R et al. (2002) Pimecrolimus (SDZ ASM 981) cream: good tolerability in paediatric patients (conference abstract). 20th World Congress of Dermatology, July 1–5, 2002, Paris. Ann Dermatol Venereol 129:1S411

  24. Ho V, Halbert A, Takoaka R et al. (2001) Pimecrolimus (Elidel®, SDZ ASM 981) Cream 1% is effective and safe in infants aged 3–23 months with atopic dermatitis (conference abstract). JEADV 15 [Suppl 2]:110

  25. Kapp A, Papp K, Bingham A et al. (2002). Efficacy and safety of pimecrolimus cream, a novel non-steroid anti-inflammatory, in long-term management of atopic dermatitis in infants. J Allergy Clin Immunol 110:277–284

    Google Scholar 

  26. Wahn U, Bos JD, Goodfield M et al. (2002) Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110:e2

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum der Dermatologie und Venerologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main

    D. Thaçi

  2. Zentrum der Dermatologie und Venerologie, J.W. Goethe-Universität, Frankfurt/Main, Theodor-Stern-Kai 7, 60590 , Frankfurt/Main

    D. Thaçi

Authors
  1. D. Thaçi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Thaçi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thaçi, D. Langzeitmanagement des atopischen Ekzems bei Kindern mit Calcineurininhibitoren. Hautarzt 54, 418–423 (2003). https://doi.org/10.1007/s00105-003-0524-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-003-0524-3

Schlüsselwörter

Keywords

Search

Navigation